#South Korea #Incheon #SK bioscience #Vaccine Development #ROTOR

SK bioscience Launches AI-Powered Initiative to Reduce Uncertainty in Vaccine Development Decisions

In a groundbreaking move, SK bioscience has announced its leadership in the Research Optimization & Trial Outcome Recommender (ROTOR) project, which is supported by the Gates Foundation. This initiative is a significant step towards establishing a global collaboration framework aimed at enhancing vaccine development through artificial intelligence (AI).

The ROTOR project, which includes partnerships with the global health nonprofit PATH and the consulting firm Slalom, focuses on creating an AI-powered platform to aid in evidence-based clinical decision-making. This project aims particularly at supporting the next-generation injectable rotavirus vaccine's development while also advancing vaccine accessibility in low- and middle-income countries (LMICs).

The Technology Behind ROTOR

The ROTOR platform is designed to effectively analyze various clinical, immunogenicity, and scientific datasets collected during the vaccine development process. By integrating these diverse datasets, the platform will optimize research and development (R&D) decision-making processes, fostering evidence-based decisions even amidst uncertainty. The ultimate goal is to evolve this platform into a scalable AI solution applicable across numerous vaccine types and diseases.

Utilizing insights and datasets gathered from both SK bioscience and PATH on rotavirus vaccine development, ROTOR aims to bolster R&D capabilities among vaccine developers in LMICs. The initiative is poised to create reusable components that can facilitate broader application within the vaccine development ecosystem.

Typically, decisions in pharmaceutical development regarding progression to large-scale Phase III clinical trials rely heavily on results from Phase II trials. However, this can be especially challenging in vaccine fields like rotavirus, where validated immune correlates of protection may be limited or vary across methodologies. Given that Phase III trials require substantial financial investment and long-term commitments, a more scientific and streamlined decision-making framework has become increasingly vital.

The ROTOR platform looks to mitigate these issues by applying AI to synthesize extensive clinical and research datasets, integrating various scientific evidence sources, and generating structured insights for vaccine developers. This innovative approach promises to enhance the development efficiency of vaccine programs significantly.

Leveraging Collaborations for Global Health

SK bioscience has a robust history of collaborating with prominent global public health organizations, including the World Health Organization (WHO), Coalition for Epidemic Preparedness Innovations (CEPI), and the U.S. Centers for Disease Control and Prevention (CDC). These relationships have been instrumental in strengthening global health infrastructure and expanding access to vaccines.

In its commitment to enhancing vaccine availability, SK bioscience has recently signed a licensing agreement with the CDC to develop an injectable rotavirus vaccine and has engaged in agreements with the Gates Medical Research Institute for novel RSV (Respiratory Syncytial Virus) antibody therapy. The company is further advancing its pipeline of infectious disease solutions, which includes vaccines for Ebola and cell-culture-based avian influenza, aiming to establish itself as a leading global vaccine provider.

According to Jaeyong Ahn, CEO of SK bioscience, “This project represents a new approach to reducing uncertainty in vaccine development through AI and enabling more scientific and efficient decision-making. Through this consortium, we aim to drive innovation in vaccine R&D while contributing to improved vaccine access worldwide.”

Advancing AI-Driven Innovations

SK bioscience continues to invest in AI-driven innovations across its R&D operations. By establishing AI-assisted experimental design systems informed by extensive research and manufacturing data, the company seeks to enhance efficiency in vaccine development, thereby reducing timelines and improving decision-making processes. They are also incorporating digital twin technologies to further enhance AI-based analytics in an ongoing digital transformation effort.

Conclusion

Through the ROTOR project, SK bioscience is not only enhancing its own capabilities but is also setting a precedent for how AI can transform vaccine development. This forward-thinking initiative embodies a significant advancement in global health efforts and emphasizes a commitment to making vaccines more accessible to those in need.